FINWIRES · TerminalLIVE
FINWIRES

$OSCR

10 stories mentioning OSCRUpdated just now

Every FINWIRES story that references OSCR, newest first.

Wire

Oscar Health Swings to Q2 Profit, Revenue Rises; 2026 Revenue Outlook Reaffirmed

Oscar Health (OSCR) reported Q2 earnings Thursday of $1.10 per diluted share, compared with a loss of $0.89 a year earlier.Analysts surveyed by FactSet expected $0.40.Revenue for the quarter ended June 30 was $4.88 billion, up from $2.86 billion a year earlier.Analysts expected $4.73 billion.The company said it continues to expect 2026 revenue of $18.7 billion to $19 billion. Analysts are looking for $12.48 billion.Shares of the company rose more than 16% in recent premarket activity Thursday.Price: $35.10, Change: $+4.99, Percent Change: +16.57%

$OSCR
Research

Barclays Upgrades Oscar Health to Overweight From Equalweight, Raises Price Target to $35 From $30

Oscar Health (OSCR) has an average rating of hold and mean price target of $22.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$OSCR
Wire

Oscar Health Shares Rise After Wells Fargo Upgrade

Oscar Health (OSCR) shares rose more than 16% in late Thursday trading after Wells Fargo upgraded the health insurer to equalweight from underweight and raised its price target to $20 from $11.Trading volume stood at over 7.9 million shares compared with a daily average of about 7.2 million shares.Price: $23.82, Change: $+3.32, Percent Change: +16.20%

$OSCR
Research

Wells Fargo Upgrades Oscar Health to Equalweight From Underweight, Adjusts PT to $20 From $11

Oscar Health (OSCR) has an average rating of hold and mean price target of $22.18, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$OSCR
Insider Trading

Oscar Health Insider Sold Shares Worth $2,316,031, According to a Recent SEC Filing

Richard Scott Blackley, Chief Financial Officer, on May 14, 2026, sold 100,000 shares in Oscar Health (OSCR) for $2,316,031. Following the Form 4 filing with the SEC, Blackley has control over a total of 1,291,660 Class A common shares of the company, with 1,216,660 shares held directly and 75,000 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1568651/000152502026000007/xslF345X05/wk-form4_1779135348.xml

$OSCR
Wire

UBS Adjusts Price Target on Oscar Health to $20 From $15, Maintains Neutral Rating

Oscar Health (OSCR) has an average rating of hold and mean price target of $18.91, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $20.16, Change: $+0.33, Percent Change: +1.66%

$OSCR
Sectors

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks were higher late Wednesday afternoon, with the NYSE Health Care Index increasing 0.3% and the State Street Health Care Select Sector SPDR ETF (XLV) adding 0.2%.The iShares Biotechnology ETF (IBB) climbed up 2.1%.In corporate news, Oscar Health (OSCR) shares surged past 10% after the company reported higher Q1 results.DaVita (DVA) shares jumped past 22% after Deutsche Bank upgraded the stock to buy from hold and boosted its price target to $220 from $126, a day after the company reported better-than-expected Q1 results.CVS Health (CVS) raised its full-year earnings outlook after reporting better-than-expected Q1 results on improvement in its health-care benefits segment. Its shares gained 8%.Novo Nordisk (NVO) expects generic versions of its Ozempic medication to face approval delays in China until next year, Bloomberg reported, citing the drugmaker. The patent for semaglutide, the main ingredient in Ozempic and Wegovy, expired in China in March, but the firm said it still has regulatory data protection until April 2027 due to a trade agreement between China and Switzerland, Bloomberg reported. Novo shares rose 2.2%.

$CVS$DVA$NVO$OSCR
Wire

Update: Oscar Health Shares Rise After Higher Q1 Results

(Updates with the latest stock movement in the first paragraph and headline.)Oscar Health (OSCR) shares were up past 10% in Wednesday afternoon trading after the company reported higher Q1 results.The company reported Q1 adjusted earnings Wednesday of $2.07 per diluted share, up from $0.92 a year earlier.Analysts polled by FactSet expected $1.11.Revenue for the quarter ended March 31 was $4.65 billion, up from $3.05 billion a year earlier.Analysts surveyed by FactSet expected $4.90 billion.The company reaffirmed its full-year 2026 guidance across all metrics.Price: $19.79, Change: $+1.85, Percent Change: +10.32%

$OSCR
Sectors

Sector Update: Health Care Stocks Gain Pre-Bell Wednesday

Health care stocks were higher premarket Wednesday, with the State Street Health Care Select Sector SPDR ETF (XLV) gaining by 0.1% and the iShares Biotechnology ETF (IBB) advancing 1%.Novo Nordisk (NVO) stock was up more than 6% premarket after the company posted higher-than-expected Q1 earnings and revenue in addition to raising its 2026 adjusted sales growth guidance.Royal Philips (PHG) shares were up more than 1% pre-bell after the company reported higher-than-expected Q1 adjusted income from continuing operations and revenue.Oscar Health (OSCR) stock was up over 9% premarket after the company reported higher Q1 adjusted earnings and revenue.

$IBB$NVO$OSCR$PHG$XLV
Research

Jefferies Upgrades Oscar Health to Hold From Underperform, Adjusts Price Target to $16 From $10

Oscar Health (OSCR) has an average rating of hold and mean price target of $16.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$OSCR

Track with the FINWIRES app suite

FolioX
FolioX
Track OSCR in your portfolio
WheelAI
WheelAI
Analyze OSCR options with the wheel strategy
StockInsider
StockInsider
See market sentiment on OSCR